Narrative review: BRAF opens the door for therapeutic advances in melanoma.

摘要: Patients with metastatic melanoma have a poor prognosis and limited treatment options. In about one half of analyzed patients melanoma, mutated signal transduction molecule has been identified: v-raf murine sarcoma viral oncogene homolog B1 (BRAF). This is part an intracellular signaling cascade may play role in many different types cancer. article provides overview the current options for describes pathophysiology underlying development therapies based on inhibition BRAF. It summarizes findings phase 1 2 studies BRAF inhibitor therapy primarily who shown objective response rates 70% to 80%. However, initial responses not sustained, median time relapse approximately 9 months. Clinicians should be aware 3 trials these agents combining other novel because, at minimum, inhibitors seem valuable as palliative melanoma.